Please select the option that best describes you:
In light of data from PRODIGE7, for patients with peritoneal metastasis from colon cancer, do you still offer HIPEC?
If so, how much systemic therapy would you give before considering surgery?
Answer from: Medical Oncologist at Community Practice
I think the PRODIGE 7 trial, while “negative” for the addition of HIPEC to cytoreduction, was an important trial in highlighting a potentially useful treatment approach for metastatic colorectal cancer with peritoneal only disease.
The median survivals are encouraging for patients who r...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
In my practice, I leave the decision use HIPEC in addition CRS to my surgical colleagues. Of late, I have seen a roughly 50/50 split in HIPEC/No HIPEC use, largely related to disease burden at the time of surgery.
As for the pre-operative chemotherapy, these patients will all get at least 6 months ...